DHE As An Acute Migraine Therapy Post-Preventive Approvals
The director of the Dartmouth Headache Clinic at Dartmouth-Hitchcock Medical Center spoke about the potential of a DHE therapy for acute migraine treatment.
Drugs and Creativity: Fact or Fiction?
Creativity, a human ability that provides artistic, organizational, and scientific innovation, moves the world forward. Do drugs that alter perception help or hinder that process?
ALS-Specific Cognitive, Behavioral Changes Associated with Advancing Disease Stage
The relationship between disease stage and behavior is important given the strength of the relationship relative to cognition and its negative impact on patients and caregivers.
Pitolisant Reduces ESS Scores Up to 5 Years in Patients with Excessive Daytime Sleepiness
By the open-label extension’s end, those treated with pitolisant showed a decrease in ESS score by 6.2 from baseline.
The Recent Revolution in Acute Stroke Care
The co-director of the UPMC’s Center for Endovascular Therapy spoke about the gains that stroke care has made in the last few years.
Clearing Up Confusion About Cannabidiol for Dravet Syndrome
The idea of marijuana as a panacea for neurologic conditions has come into play, leading to a need for clarification about the use of CBD for these conditions.
Insomnia Treatment Moving Toward Precision Medicine
Rachel Salas, MD, a Johns Hopkins Associate Professor, spoke about insomnia, a very individualized disorder, and the need for moving toward precision medicine.
Early Monitoring of Antiepileptic Drugs Could Prevent Increased Seizure Frequency During Pregnancy
Study findings revealed that AED clearance significantly changes by the first trimester for levetiracetam and by the second trimester for oxcarbazepine and topiramate.
Reintroducing DHE for Acute Migraine Treatment
As a phase III trial of DHE gets underway, the director of the Dartmouth Headache Clinic at Dartmouth-Hitchcock Medical Center spoke about its clinical history in the United States.
Patricia K. Coyle, MD: Early Multiple Sclerosis Identification
The director of the Comprehensive Multiple Sclerosis Center at Stony Brook Neuroscience Institute spoke about the importance of early treatment and identification of the condition.
Multiple Sclerosis Disability Evolution Risk Profile Informs Personalized Treatment
A real-world study in relapsing MS helped develop a risk score scale to aid in disability progression prediction, and thus, treatment strategies.
Fred Lublin, MD: Beginning to Treat Progressive Multiple Sclerosis
The MS expert discussed the field's recent foray into treating progressive forms of the disease and what is in development.
XEN496 Being Developed for KCNQ2 Epileptic Encephalopathy
Xenon Pharmaceuticals announced the expansion of its ion channel pipeline as a result of feedback from the FDA.
Striving for Full Seizure Control in Epilepsy, LGS, Dravet Syndrome
The director of the Epilepsy Program at the Banner University Medical Center spoke about the needs in patient populations with epilepsy.
The Current State of Sleep Apnea with Rachel Salas, MD
The Johns Hopkins Associate Professor discussed the current of state sleep and also dove into the therapeutic landscape of sleep apnea.
Patricia K. Coyle, MD: Disease-Modification in Multiple Sclerosis
While there isn’t one agent Coyle believes is held above the rest, she noted that the oral therapies have become popular due to ease of administration.
ARM210 Granted Orphan Drug Designation for RYR1-RM Treatment
Also known as S48168, it was previously granted Orphan Drug designation as well as a Rare Pediatric Disease designation in 2015 for Duchenne Muscular Dystrophy.
Riluzole Oral Suspension Granted FDA Approval for ALS
The approval was based on bioavailability studies which compared the tablet formulation of riluzole to the oral suspension formulation.
Addressing Misdiagnosis of CIDP by Sticking to the Guidelines
The director of the electromyography laboratory and a professor of neurology at Cedars-Sinai discussed the misdiagnosis of the rare condition.
Neurological Manifestations of HIV
Neurologic complications remain a significant cause of long-term disability. Understanding and recognizing these conditions is crucial in effectively managing HIV.
Phase II Trial of HisproUK, Low-Dose tPA Dual Therapy for Ischemic Stroke Initiated
The dual-therapy regimen will be compared to high-dose tPA monotherapy, the standard of care, in patients with distal blood clots post-stroke.
LYS-SAF302 Granted IND Clearance for Phase II-III Trial in MPS IIIA
Previously, in a 5-year phase I-II trial, the rAAV vector serotype rh.10 showed promising safety data.
Fred Lublin, MD: The Primary Care Partnership in Multiple Sclerosis
The director of the Corinne Goldsmith Dickinson Center for Multiple Sclerosis at Mount Sinai Medical Center spoke about the relationship between primary care and specialists.
Diagnosing Migraine, Knowing the Basics
Berk spoke to the important partnership between primary care and specialists in neurology.
Trial Data Models Patient Transport for Suspected Stroke with Large-Vessel Occlusion
For ischemic stroke with suspected large-vessel occlusion, regional centralization of care is estimated to result in the best outcomes.
Hand-Me-Downs: The CIDP Therapeutic Landscape
The director of the electromyography laboratory and a professor of neurology at Cedars-Sinai spoke about the treatment options for CIDP.
The Importance of Identifying Responders in Migraine
With the pending decision on 2 more CGRP agents, the need for biomarkers to identify responders has never been greater.
Peter Goadbsy, MD, PhD, DSc: Differentiating Between CGRPs, Synthesizing the Gepants
Goadsby spoke about differentiating between the foursome of preventive therapies soon to be available to physicians.
Fred Lublin, MD: The Need for Biomarkers in Multiple Sclerosis
The Saunders Family Professor of Neurology and the director of the Corinne Goldsmith Dickinson Center for Multiple Sclerosis at Mount Sinai Medical Center discussed the need for biomarkers in MS.
A Bright Horizon for Migraine Treatments
Thomas Berk, MD, discussed the current therapeutic landscape of migraine, emphasizing the importance of conversing with each patient to identify an individualized approach.
